PHARMACYTE BIOTECH, INC. Gains (Losses) on Restructuring of Debt
PHARMACYTE BIOTECH, INC. (PMCB) reported Gains (Losses) on Restructuring of Debt of $0 for the 12-month period ending 2016-04-30, per its 10-K filed 2016-07-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnRestructuringOfDebt · last filed 2016-07-29
- PHARMACYTE BIOTECH, INC. gains (losses) on restructuring of debt for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- PHARMACYTE BIOTECH, INC. gains (losses) on restructuring of debt for fiscal 2015 was $3.34M.
- PHARMACYTE BIOTECH, INC. gains (losses) on restructuring of debt for fiscal 2014 was $0.00.
- PHARMACYTE BIOTECH, INC. gains (losses) on restructuring of debt for fiscal 2013 was $0.00.
| Period end | Gains (Losses) on Restructuring of Debt 12 month |
|---|---|
| 2016-04-30 | $0.00 10-K · filed 2016-07-29 |
| 2015-04-30 | $3.34M 10-K · filed 2016-07-29 |
| 2014-04-30 | $0.00 10-K · filed 2016-07-29 |
| 2013-04-30 | $0.00 10-K/A · filed 2016-01-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |